BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27531777)

  • 1. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
    Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Influence of CD117 Expression on Response of Multiple Myeloma Patients to Chemotherapy].
    Tang HL; Shu MM; Dong BX; Gu HT; Liang R; Bai QX; Yang L; Zhang T; Gao GX; Chen XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1346-51. PubMed ID: 26524035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
    Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.
    Shin SY; Lee ST; Kim HJ; Kim SJ; Kim K; Kang ES; Kim SH
    J Clin Lab Anal; 2015 Nov; 29(6):505-10. PubMed ID: 25277787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.
    Kaufmann H; Krömer E; Nösslinger T; Weltermann A; Ackermann J; Reisner R; Bernhart M; Drach J
    Eur J Haematol; 2003 Sep; 71(3):179-83. PubMed ID: 12930318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
    Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
    Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunophenotype characteristics of patients with multiple myeloma in different risk stratification].
    Hu K; Wang J; Zhu MX; Wang YF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1624-7. PubMed ID: 25543486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
    J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma.
    Li C; Chen L; Gao X; Qu X; Shen W; Yang R; Zhang R; Qiu H; Xu J; Lu H; Li J
    Leuk Lymphoma; 2011 Feb; 52(2):260-4. PubMed ID: 21133734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
    Mateo G; Montalbán MA; Vidriales MB; Lahuerta JJ; Mateos MV; Gutiérrez N; Rosiñol L; Montejano L; Bladé J; Martínez R; de la Rubia J; Diaz-Mediavilla J; Sureda A; Ribera JM; Ojanguren JM; de Arriba F; Palomera L; Terol MJ; Orfao A; San Miguel JF; ;
    J Clin Oncol; 2008 Jun; 26(16):2737-44. PubMed ID: 18443352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients.
    Awasthi NP; Mishra S; Gupta G; Kumari S; Bajpayee A; Singh P; Husain N
    Indian J Pathol Microbiol; 2023; 66(2):295-300. PubMed ID: 37077071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma.
    Pan Y; Wang H; Tao Q; Zhang C; Yang D; Qin H; Xiong S; Tao L; Wu F; Zhang J; Zhai Z
    Leuk Res; 2016 Jan; 40():77-82. PubMed ID: 26597998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of VEGF Expression with Serous Effusion in Multiple Myeloma Patients].
    Zhang PP; Zhang F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1134-1138. PubMed ID: 35981373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application Value of CD138 MACS-FISH in the Genetic Diagnosis of Plasma Cell Dyscrasia].
    Mei JG; Li HQ; Cao HQ; Shao JJ; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1437-1442. PubMed ID: 27784371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
    Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.